苯甲基四氢哒嗪-1(2H)-甲酸基酯 | 124072-88-4

• 物质功能分类: 医药中间体 - 哒嗪类化合物
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 苯甲基四氢哒嗪-1(2H)-甲酸基酯
• 英文名称: tetrahydropyridazine-1-carboxylic acid benzyl ester
• 英文别名: 1-benzyl tetrahydropyridazine-(2H)-carboxylate；1-benzyloxycarbonylperhydropyridazine；Benzyl tetrahydropyridazine-1(2H)-carboxylate；benzyl diazinane-1-carboxylate
• CAS: 124072-88-4
• 化学式: C₁₂H₁₆N₂O₂
• 分子量: 220.271
• InChiKey: FSUYCTZYHDQXDW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  16
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.42
• 拓扑面积：
  41.6
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  苯甲基四氢哒嗪-1(2H)-甲酸基酯 在 copper diacetate 、 氧气 、 四氯化钛 作用下， 以 四氢呋喃 、 异丙醇 为溶剂， 反应 30.25h， 生成 3-cyanotetrahydropyridazine-1-carboxylic acid benzyl ester
  参考文献：
  名称：

  Formation of Unnatural Cyclic Amino Acid Equivalent from the Simple Cyclic Hydrazine

  摘要：

  DOI：

  10.3987/com-04-10153
• 作为产物：
  描述：

  2-(叔丁氧基羰基)六氢吡嗪-1-羧酸苄酯 在 三氟乙酸 作用下， 以 二氯甲烷 为溶剂， 生成 苯甲基四氢哒嗪-1(2H)-甲酸基酯
  参考文献：
  名称：

  Synthesis, molecular modeling and biological evaluation of aza-proline and aza-pipecolic derivatives as FKBP12 ligands and their in vivo neuroprotective effects

  摘要：

  Nonimmunosuppressant ligands, exemplified by GPI 1046 (1), for the peptidyl-prolyl isomerase FKBP12 have been found to unexpectedly possess powerful neuroprotective and neuroregenerative effects in vitro and in vivo. We have extensively explored the therapeutic utility of FKBP12 ligands based on analogues of proline and pipecolic acid. As part of our ongoing program to explore novel structural classes of FKBP12 ligands, we herein wish to report a new class of FKBP12 ligands containing aza-proline and aza-pipecolic acid analogues. Details of the synthetic studies, together with biological activity will be presented. (C) 2003 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/s0968-0896(03)00478-4

文献信息

• New Histidyl amino acid derivatives, and pharmaceutical composition
  申请人：Fujisawa Pharmaceutical Co., Ltd.

  公开号：US04921855A1

  公开（公告）日：1990-05-01

  A compound of the formula: ##STR1## wherein R.sup.1 is lower alkyl optionally substituted with a substituent selected from the group consisting of acyl, hydroxy, lower alkoxy, aryl, lower alkylthio and a group of the formula: ##STR2## in which R.sup.5 is hydrogen or acyl and R.sup.6 is hydrogen or lower alkyl; aryl; or amino optionally substituted with substituent(s) selected from the group consisting of lower alkyl and acyl; and R.sup.2 is hydrogen or lower alkyl; or R.sup.1 and R.sup.2 are taken together with the attached nitrogen atom to form a heterocyclic group optionally substituted with substituent(s) selected from the group consisting of lower alkyl, hydroxy(lower )alkyl, lower alkoxy(lower)alkyl, acyl(lower)alkyl, oxo and acyl; R.sup.3 is hydrogen or lower alkyl; and R.sup.4 is lower alkyl; and its pharmaceutically acceptable salt, processes for the preparation thereof and pharmaceutical composition comprising the same.

  该化合物的化学式如下：##STR1##其中R.sup.1是选择自酰基、羟基、较低烷氧基、芳基、较低烷硫基和化学式组成的取代基的较低烷基，其中R.sup.5是氢或酰基，R.sup.6是氢或较低烷基；芳基；或氨基，可选择地带有来自较低烷基和酰基的取代基，R.sup.2是氢或较低烷基；或R.sup.1和R.sup.2与相连的氮原子一起形成可选择地带有来自较低烷基、羟基(较低)烷基、较低烷氧基(较低)烷基、酰基(较低)烷基、氧代基和酰基的取代基的杂环基；R.sup.3是氢或较低烷基；R.sup.4是较低烷基；以及其药学上可接受的盐、其制备方法和包含其的药物组合物。
• New amino acid derivatives, processes for the preparation thereof and pharmaceutical composition comprising the same
  申请人：FUJISAWA PHARMACEUTICAL CO., LTD.

  公开号：EP0300189A2

  公开（公告）日：1989-01-25

  A compound of the formula : wherein R1 is lower alkyl optionally substituted with a substituent selected from the group consisting of acyl,hydroxy, lower alkoxy, aryl, lower alkylthio and a group of the formula : in which R5 is hydrogen or acyl and R6 is hydrogen or lower alkyl; aryl; or amino optionally substituted with substituent(s) selected from the group consisting of lower alkyl and acyl; and R2 is hydrogen or lower alkyl; or R1 and R2 are taken together with the attached nitrogen atom to form a heterocyclic group optionally substituted with substituent(s) selected from the group consisting of lower alkyl, hydroxy(lower)alkyl, lower alkoxy(lower)alkyl, acyl(lower)alkyl, oxo and acyl; R3 is hydrogen or lower alkyl; and R4 is lower alkyl; and its pharmaceutically acceptable salt, processes for the preparation thereof and pharmaceutical composition comprising the same.

  一种式如下的化合物 其中 R1 是低级烷基，可任选被选自以下组别的取代基取代：酰基、羟基、低级烷氧基、芳基、低级烷硫基和一个式......的基团： 其中 R5 为氢或酰基，且 R6 是氢或低级烷基；芳基；或被选自低级烷基和酰基的取代基任选取代的氨基；以及 R2 是氢或低级烷基；或 R1 和 R2 与所连接的氮原子一起形成杂环基团，该杂环基团可任选被选自由低级烷基、羟基（低级）烷基、低级烷氧基（低级）烷基、酰基（低级）烷基、氧代和酰基组成的取代基取代； R3 是氢或低级烷基；和 R4 是低级烷基； 及其药学上可接受的盐、制备工艺和包含这些成分的药物组合物。
• The Synthesis, Structure and Reactivity of 1-Thioxotetrahydropyridazino[1,2-a][1,2,4]triazin-4(1H)-one
  作者：Sandra Jarrett、Ainka Brown、Marvadeen Singh-Wilmot

  DOI：10.3987/com-09-11768

  日期：——

  The synthesis of 1-thioxotetrahydropyridazino[ 1,2-a][1,2,4]triazin-4(1H)-one 3 in five steps from tert-butyl carbazate and its transformation into 3-benzylidene and 1-amino derivatives are described. Its crystal structure is presented showing it to be an axially chiral molecule that exists as a racemate in the solid state.
• Synthesis and conformational preferences in solution and crystalline states of an aza-tripeptide
  作者：Christine Hemmerlin、Manh Thong Cung、Guy Boussard

  DOI：10.1016/s0040-4039(01)00917-0

  日期：2001.7

  The aza-tripeptide Boc-Ala-AzPip-Ala-NHiPr (AzPip: 2-aza pipecolyl residue) was synthesized in seven steps using preferentially the diisopropylcarbodiimide; 1-hydroxy-7-aza-benzotriazole (DIPCDI/AtOH) coupling method and via the Boc-AzPip-OBzl pivotal intermediate. Its crystal molecular structure is characterized bq; the: presence of a beta Vl-like turn around the N-terminal Ala-AzPip sequence and stabilized by two intramolecular hydrogen bonds sharing the same (Boc)CO carbonyl acceptor. In solution (chloroform, DMSO), two isomers are in equilibrium, one of them resembling the stereoisomer found in the crystal. the other bring unfolded, but keeping the cis-isomerism of the Ala-AzPip bond and the pronounced degree of pyramidicity of the axial 2-amide N-x nitrogen atom. (C) 2001 Elsevier Science Ltd. All rights reserved.
• US4921855A
  申请人：——

  公开号：US4921855A

  公开（公告）日：1990-05-01